Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H1 2018

March 2018 | 69 pages | ID: G64FD6F5E7BEN
Global Markets Direct

Abstracts

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H1 2018

SUMMARY

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies.

The latest report GrowthDifferentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H1 2018, outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGF?) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large.

The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 4, 1 and 7 respectively. Report covers products from therapy areas Genetic Disorders, Musculoskeletal Disorders, Central Nervous System, Gastrointestinal, Hematological Disorders, Metabolic Disorders and Oncology which include indications Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis, Muscular Dystrophy, Sarcopenia, Anemia, Becker Muscular Dystrophy, Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth Disease Type I, Crohn's Disease (Regional Enteritis), Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Fibrosis, Insulin Resistance, Myelodysplastic Syndrome, Myelofibrosis, Sickle Cell Disease, Spinal Muscular Atrophy (SMA) and Thalassemia.

Furthermore, this report also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
• The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics and enlists all their major and minor projects
• The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope

Contents

Introduction
Global Markets Direct Report Coverage
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Overview
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Companies Involved in Therapeutics Development
Acceleron Pharma Inc
Amgen Inc
Bioleaders Corp
F. Hoffmann-La Roche Ltd
PeptiDream Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
Sarepta Therapeutics Inc
Scholar Rock Inc
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Drug Profiles
ACE-083 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACE-2494 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACE-2798 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATA-842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLS-ILB-MD1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
domagrozumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
luspatercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSX-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-2477 + trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRK-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Myostatin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
talditercept alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Dormant Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Discontinued Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Product Development Milestones
Featured News & Press Releases
Feb 28, 2018: Acceleron Announces Publication of ACE-083 Phase 1 Trial Results in Muscle & Nerve
Feb 08, 2018: Acceleron Announces Appointment of Chief Commercial Officer
Feb 02, 2018: Scholar Rock Announces Publication of Comprehensive Pharmacological Study of SRK-015, a Novel Inhibitor of Myostatin Activation, Supporting the Treatment of Muscle Atrophy Disorders
Jan 23, 2018: Scholar Rock and Collaborators at Harvard Medical School and Northeastern University Elucidate Molecular Basis of Myostatin Activation - a Key Physiological Process in Muscle Health
Jan 08, 2018: Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy
Dec 10, 2017: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology
Nov 01, 2017: Acceleron to Present Clinical Presentations on Investigational Drug Candidate Luspatercept at 59th American Society of Hematology Annual Meeting and Exposition
Sep 19, 2017: Acceleron Provides Clinical Update on Luspatercept at 2017 R&D Day
Sep 19, 2017: Acceleron Provides Clinical Update on Muscular Dystrophy Drug Candidate ACE-083 at 2017 R&D Day
Sep 19, 2017: Acceleron Provides Update on Clinical Development Plans for ACE-2494 at 2017 R&D Day
Sep 14, 2017: Scholar Rock Announces Issuance of Broad Patent Covering Therapeutic Approach for Neuromuscular Diseases
Sep 05, 2017: Acceleron Announces Publication of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results in The Lancet Oncology
Aug 01, 2017: Acceleron Announces First Patient Treated in Phase 2 Clinical Trial of ACE-083 in Charcot-Marie-Tooth Disease
Jul 10, 2017: Scholar Rock and the Miami Project to Cure Paralysis Present Preclinical Data Demonstrating Therapeutic Potential of SRK-015 in Spinal Cord Injury at 35th Annual National Neurotrauma Symposium
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Acceleron Pharma Inc, H1 2018
Pipeline by Amgen Inc, H1 2018
Pipeline by Bioleaders Corp, H1 2018
Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Pipeline by PeptiDream Inc, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
Pipeline by Sarepta Therapeutics Inc, H1 2018
Pipeline by Scholar Rock Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Acceleron Pharma Inc
Amgen Inc
Bioleaders Corp
F. Hoffmann-La Roche Ltd
PeptiDream Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
Sarepta Therapeutics Inc
Scholar Rock Inc